{
  "acknowledgement": [
    {
      "confidence": [
        1
      ],
      "excerpt": "* Supervisors:\n  * Dr.Nilanjan Ray, Associate Professor, Department of Computing Science, University of Alberta, Canada\n  * Dr.Gilbert Bigras, Associate Professor, Department of Laboratory Medicine & Pathology, University of Alberta, Canada\n* Dataset: https://bit.ly/2MdWSzp\n* Citation: \n  * https://www.ncbi.nlm.nih.gov/pubmed/27093450\n  * https://arxiv.org/abs/1409.1556\n  * https://arxiv.org/abs/1905.11946\n* Reference: https://www.healthline.com/health/lymphoma#diagnosis\n\n",
      "technique": "Header extraction"
    }
  ],
  "arxivLinks": {
    "confidence": [
      1.0
    ],
    "excerpt": [
      "https://arxiv.org/abs/1409.1556\n  * https://arxiv.org/abs/1905.11946\n* Reference: https://www.healthline.com/health/lymphoma#diagnosis\n\nFeedback\n==========\nPlease send me your feedback at sandipsahajoy@ualberta.ca",
      "https://arxiv.org/abs/1905.11946\n* Reference: https://www.healthline.com/health/lymphoma#diagnosis\n\nFeedback\n==========\nPlease send me your feedback at sandipsahajoy@ualberta.ca"
    ],
    "technique": "Regular expression"
  },
  "citation": [
    {
      "confidence": [
        0.8283216015784888
      ],
      "excerpt": "| Hematoxylin(blue counterstrain) | Hematoxylin(blue counterstrain) | \n",
      "technique": "Supervised classification"
    }
  ],
  "codeRepository": {
    "confidence": [
      1.0
    ],
    "excerpt": "https://github.com/sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras",
    "technique": "GitHub API"
  },
  "dateCreated": {
    "confidence": [
      1.0
    ],
    "excerpt": "2019-12-19T05:26:03Z",
    "technique": "GitHub API"
  },
  "dateModified": {
    "confidence": [
      1.0
    ],
    "excerpt": "2020-05-21T15:47:02Z",
    "technique": "GitHub API"
  },
  "description": [
    {
      "confidence": [
        0.9803713218456204,
        0.9872218233305955
      ],
      "excerpt": "Classifying histopathology slides of Lymphoma as malignant or benign using Convolutional Neural Network(CNN) \nThis project serves as a demonstration of how deep convolutional neural networks can achieve high accuracies in cancer histopathological image classification. The data used in this model was from Cross Cancer Institute, Edmonton, AB, curated by pathologist Dr.Gilbert Bigras. He digitized each of the 113 Lymphoma MYC IHC slides and labeled images as benign and malignant. The project was supervised by Dr.Nilanjan Ray. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9766709971889473,
        0.8656499619292638,
        0.9598698428969638
      ],
      "excerpt": "Neural networks are a set of algorithms, modeled loosely after the human brain, that are designed to recognize patterns. They interpret sensory data through a kind of machine perception, labeling or clustering raw input. The patterns they recognize are numerical, contained in vectors, into which all real-world data, be it images, sound, text or time series, must be translated. (Skymind.ai) \nWhat is lymphoma? \nThe lymph system is a series of lymph nodes and vessels that move lymph fluid through the body. Lymph fluids contain infection-fighting white blood cells. Lymph nodes act as filters, capturing and destroying bacteria and viruses to prevent infection from spreading. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9189394022839878
      ],
      "excerpt": "Doctors classify more than 70 cancer types as lymphomas. Lymphomas can affect any portion of the lymphatic system, including: \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9524508895612396,
        0.9928481903982624,
        0.9891785691729262
      ],
      "excerpt": "What are the causes of lymphoma? \nCancer is the result of uncontrolled cell growth. The average lifespan of a cell is brief, and then the cell dies. In people with lymphoma, however, the cell thrives and spreads instead of dying. It\u2019s unclear what causes lymphoma, but a number of risk factors are connected with these cancers. \nHow is lymphoma diagnosed? \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9130330596920921,
        0.9657966390930655
      ],
      "excerpt": "What are the types of lymphoma? \nThe two major lymphoma types are Hodgkin\u2019s lymphoma and non-Hodgkin\u2019s lymphoma (NHL). A pathologist in the 1800s named Dr. Thomas Hodgkin identified the cells in what is now called Hodgkin\u2019s lymphoma. Those with Hodgkin\u2019s lymphoma have large cancerous cells called Reed-Sternberg (RS) cells. People with NHL don\u2019t have these cells. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9826005376060347
      ],
      "excerpt": "According to the Leukemia & Lymphoma Society (LLS), NHL is three times more common than Hodgkin\u2019s lymphoma.Many lymphoma types fall under each category. Doctors call NHL types by the cells they affect, and if the cells are fast- or slow-growing. NHL forms in either the B-cells or T-cells of the immune system. According to LLS, most NHL types affect B-cells. Learn more about this type of lymphoma, who it affects, and where it occurs. Types include: \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9241725365995246
      ],
      "excerpt": "Diffuse large B-cell lymphoma (DLBCL) is the most aggressive type of NHL. This fast-growing lymphoma comes from abnormal B cells in the blood. It can be cured if treated, but if left untreated, it can lead to death. The stage of DLBCL helps determine your prognosis. Read more about the stages and how this lymphoma is treated. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.99310870411715
      ],
      "excerpt": "T-cell lymphoma is not as common a B-cell lymphoma; only 15 percent of all NHL cases are this type. Several types of T-cell lymphoma exist. Learn more about each one, what they cause, and who is more likely to develop them. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9945810910842141
      ],
      "excerpt": "Burkitt\u2019s lymphoma is a rare type of NHL that is aggressive and most common in people with compromised immune systems. This type of lymphoma is most common in children in sub-Saharan Africa, but it does occur in other parts of the world. Learn more about this rare type of non-Hodgkin\u2019s lymphoma. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9950361818479628
      ],
      "excerpt": "One in 5 lymphomas diagnosed in the United States are follicular lymphoma. This type of NHL, which starts in the white blood cells, is most common in older individuals. The average age of diagnosis is 60. This lymphoma is also slow-growing, so treatments begins with watchful waiting. Read more about this strategy. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9471163350249159
      ],
      "excerpt": "This subtype of B-cell lymphoma accounts for almost 10 percent of DLBCL cases. It predominantly affects women in their 20s and 30s. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9983314222258778
      ],
      "excerpt": "Small lymphatic lymphoma (SLL) is a type of slow-growing lymphoma. The cancer cells of SLL are found mostly in the lymph nodes. SLL is identical to chronic lymphocytic leukemia (CLL), but with CLL, the majority of cancer cells are found in the blood and bone marrow. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9548880326104727
      ],
      "excerpt": "Hodgkin\u2019s lymphomas typically start in B-cells or immune system cells known as Reed-Sternberg (RS) cells. While the main cause of Hodgkin\u2019s lymphoma is not known, certain risk factors can increase your chances of developing this type of cancer. Learn what these risk factors are. Hodgkin\u2019s lymphoma types include: \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9854668610463694,
        0.9882157804910161
      ],
      "excerpt": "This rare, aggressive type of lymphoma occurs in about 1 percent of lymphoma cases, and it\u2019s most commonly diagnosed in individuals in their 30s. In diagnostic tests, doctors will see normal lymphocytes with an abundance of RS cells. \nPatients with a compromised immune system, such as those with HIV, are more likely to be diagnosed with this type of lymphoma. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9945855965977797
      ],
      "excerpt": "This type of lymphoma is more common in men, and it accounts for about 5 percent of Hodgkin\u2019s lymphoma cases. Lymphocyte-rich Hodgkin\u2019s disease is typically diagnosed at an early stage, and both lymphocytes and RS cells are present in diagnostic tests. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9869627254503273
      ],
      "excerpt": "Like with lymphocyte-rich Hodgkin\u2019s disease, mixed cellularity Hodgkin\u2019s lymphoma contains both lymphocytes and RS cells. It\u2019s more common \u2014 almost a quarter of Hodgkin\u2019s lymphoma cases are this type \u2014 and it\u2019s more prevalent in older adult men. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9955761803384845,
        0.982037406437087
      ],
      "excerpt": "Nodular lymphocyte-predominant Hodgkin\u2019s disease (NLPHL) type of Hodgkin\u2019s lymphoma occurs in about 5 percent of lymphoma patients, and it\u2019s characterized by an absence of RS cells. \nNLPHL is most common in people between the ages of 30 and 50, and it\u2019s more common in males. Rarely, NLPHL can progress or transform into a type of aggressive NHL. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9918679967752202,
        0.9149508559083039,
        0.9185776692040343
      ],
      "excerpt": "This common type of lymphoma occurs in 70 percent of Hodgkin\u2019s cases, and it\u2019s more common in young adults than any other group. This type of lymphoma occurs in lymph nodes that contain scar tissue, or sclerosis. \nA total of 113 lymphomas (19 Burkitt\u2019s lymphoma(BL), 77 Diffuse large B-cell lymphoma(DLBCL), 6 intermediate between BL and DLBCL, and 11 unclassi\ufb01ed aggressive B-cell lymphomas) diagnosed between 2010 and 2015 with known MYC status were selected. MYC IHC stains were produced in 2014 and 2015. All specimens had been \ufb01xed in formalin (37% formaldehyde in aqueous solution) and embedded in para\ufb03n. Although a small group of cases (B20%) was studied retrospectively, all cases in this analysis were stained utilizing freshly cut thin sections. \nThe dataset consisted of 4 types of 113 whole mount slide images (2560x1920) of Lymphoma specimens scanned at 20x. From each type of master image, around 42,750 sequential non-overlapping child patches of size 100 x 100 were extracted (roughly 23,275 negative and 19,475 positive).  \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.8532317374792554
      ],
      "excerpt": "|dist_2_neg.tif|dist_7_pos.tif|Distance map of positive nuclei|2| \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.8532317374792554
      ],
      "excerpt": "| Distance map of positive nuclei  | Distance map of positive nuclei  | \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.8812926492979305
      ],
      "excerpt": "Two different model architectures are compared on the basis of performance on train-test dataset generated with 113 type-0 (MYC IHC) master images. The best one, VGG19 is selected. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9007716629187501
      ],
      "excerpt": "More details: \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.8519096341075612,
        0.9556307081836857,
        0.9767337701711148
      ],
      "excerpt": "The whole process is divided into 10 TestRuns to assure performance consistency of the models. 10 testruns are performed for each model where they are trained and evaluated on different train-test dataset generated from shuffled raw set of master images. \nSize of trainset is 90x4 and testset is 23x4 out of 113x4 master images. 113 mother images of a type is shuffled, then randomly 90 images of that type along with other 3 types holding same patientID are selected for trainset(90x4). \nFor each of the 10 TestRuns, there are 3 different versions of trained model on the basis of combination of 4 types of 113 master images. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9514969686489329
      ],
      "excerpt": "Test result of each of the 3 versions of model on each of the 10 testruns with testset size of 23 full size image. \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        1.0
      ],
      "excerpt": "Classifying histopathology slides of Lymphoma as malignant or benign using CNN",
      "technique": "GitHub API"
    }
  ],
  "downloadUrl": {
    "confidence": [
      1.0
    ],
    "excerpt": "https://github.com/sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras/releases",
    "technique": "GitHub API"
  },
  "forks_count": {
    "confidence": [
      1.0
    ],
    "excerpt": {
      "count": 0,
      "date": "Tue, 21 Dec 2021 16:13:51 GMT"
    },
    "technique": "GitHub API"
  },
  "forks_url": {
    "confidence": [
      1.0
    ],
    "excerpt": "https://api.github.com/repos/sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras/forks",
    "technique": "GitHub API"
  },
  "fullName": {
    "confidence": [
      1.0
    ],
    "excerpt": "sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras",
    "technique": "GitHub API"
  },
  "hasExecutableNotebook": {
    "confidence": [
      1.0
    ],
    "excerpt": [
      "https://raw.githubusercontent.com/sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras/master/test.ipynb",
      "https://raw.githubusercontent.com/sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras/master/train-VGGNet19.ipynb"
    ],
    "technique": "File Exploration"
  },
  "installation": [
    {
      "confidence": [
        0.9717106327039013
      ],
      "excerpt": " version 1: \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9717106327039013
      ],
      "excerpt": "* version 2: \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9717106327039013
      ],
      "excerpt": " version 3: \n",
      "technique": "Supervised classification"
    }
  ],
  "invocation": [
    {
      "confidence": [
        0.8983072892585814
      ],
      "excerpt": "<img src=\"/readme/inference/Slide2.JPG\" height=\"450\" width=\"800\" > \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.8788203098924207,
        0.8712630728315612
      ],
      "excerpt": "Each type of mother image file name is of the format: type_patientID_class.tif \n| Example    | Example     | Image Type   | Type serial | \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.8068494514088058
      ],
      "excerpt": "|2_neg.tif|7_pos.tif|MYC IHC|0| \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.8188723780362936
      ],
      "excerpt": "|hem_2_neg.tif|hem_7_pos.tif|Hematoxylin (blue counterstrain)|3| \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.929129221372287
      ],
      "excerpt": "| <img src=\"/readme/2_neg.jpg\" height=\"200\" width=\"250\" > | <img src=\"/readme/7_pos.jpg\" height=\"200\" width=\"250\" >  | \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.929129221372287
      ],
      "excerpt": "| <img src=\"/readme/dab_2_neg.jpg\" height=\"200\" width=\"250\" > | <img src=\"/readme/dab_7_pos.jpg\" height=\"200\" width=\"250\" >  | \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.929129221372287
      ],
      "excerpt": "| <img src=\"/readme/dist_2_neg.jpg\" height=\"200\" width=\"250\" > | <img src=\"/readme/dist_7_pos.jpg\" height=\"200\" width=\"250\" >  | \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.929129221372287
      ],
      "excerpt": "| <img src=\"/readme/hem_2_neg.jpg\" height=\"200\" width=\"250\" > | <img src=\"/readme/hem_7_pos.jpg\" height=\"200\" width=\"250\" >  | \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.929129221372287,
        0.8983072892585814,
        0.8983072892585814
      ],
      "excerpt": "| <img src=\"/readme/2_neg.jpg\" height=\"200\" width=\"250\" > | <img src=\"/readme/7_pos.jpg\" height=\"200\" width=\"250\" >  | \n<img src=\"/readme/inference/Slide3.JPG\" height=\"450\" width=\"800\" > \n<img src=\"/readme/inference/Slide5.JPG\" height=\"450\" width=\"800\" > \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9335498439068577
      ],
      "excerpt": "<img src=\"model architecture plot.jpg\" height=\"4000\" width=\"300\" > \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.878405400644045
      ],
      "excerpt": "| Training Version | Model Name | Image Type | Type serial | Sample | Training History <br> (TestRun1) | \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9428518195422885,
        0.9395832600350351,
        0.9450315670671492
      ],
      "excerpt": "| 1 | VGGNet19 | MYC IHC | 0 | <img src=\"/readme/2_neg.jpg\" height=\"100\" width=\"200\" > | <img src=\"/DLBCL/TestRun1/VGGNet19/acc_loss.png\" height=\"400\" width=\"525\" > \n| 2 | VGGNet19v2 | MYC IHC <br> DAB (MYC signal) <br> Distance map of positive nuclei <br> Hematoxylin (blue counterstrain) | 0 <br> 1 <br> 2 <br> 3 | <img src=\"/readme/2_neg.jpg\" height=\"100\" width=\"200\" > <br> <img src=\"/readme/dab_2_neg.jpg\" height=\"100\" width=\"200\" > <br> <img src=\"/readme/dist_2_neg.jpg\" height=\"100\" width=\"200\" > <br> <img src=\"/readme/hem_2_neg.jpg\" height=\"100\" width=\"200\" > | <img src=\"/DLBCL/TestRun1/VGGNet19v2/acc_loss.png\" height=\"400\" width=\"525\" > \n| 3 | VGGNet19v4 | MYC IHC <br> DAB (MYC signal) <br> Hematoxylin (blue counterstrain) | 0 <br> 1 <br> 3 | <img src=\"/readme/2_neg.jpg\" height=\"100\" width=\"200\" > <br> <img src=\"/readme/dab_2_neg.jpg\" height=\"100\" width=\"200\" > <br> <img src=\"/readme/hem_2_neg.jpg\" height=\"100\" width=\"200\" > | <img src=\"/DLBCL/TestRun1/VGGNet19v4/acc_loss.png\" height=\"400\" width=\"525\" > \n",
      "technique": "Supervised classification"
    },
    {
      "confidence": [
        0.9462002302298468,
        0.903281498235012
      ],
      "excerpt": "<img src=\"/readme/output.jpg\" height=\"840\" width=\"777\" > \n<img src=\"/readme/test_inference_plot.png\" height=\"2000\" width=\"750\" > \n",
      "technique": "Supervised classification"
    }
  ],
  "issueTracker": {
    "confidence": [
      1.0
    ],
    "excerpt": "https://api.github.com/repos/sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras/issues{/number}",
    "technique": "GitHub API"
  },
  "languages": {
    "confidence": [
      1.0
    ],
    "excerpt": [
      "Jupyter Notebook"
    ],
    "technique": "GitHub API"
  },
  "license": {
    "confidence": [
      1.0
    ],
    "technique": "GitHub API"
  },
  "long_title": {
    "confidence": [
      1.0
    ],
    "excerpt": "# Predicting-Lymphoma-using-CNN-in-Keras\nContext",
    "technique": "Regular expression"
  },
  "name": {
    "confidence": [
      1.0
    ],
    "excerpt": "Predicting-Lymphoma-using-CNN-in-Keras",
    "technique": "GitHub API"
  },
  "owner": {
    "confidence": [
      1.0
    ],
    "excerpt": "sandipsahajoy",
    "technique": "GitHub API"
  },
  "ownerType": {
    "confidence": [
      1.0
    ],
    "excerpt": "User",
    "technique": "GitHub API"
  },
  "readme_url": {
    "confidence": [
      1.0
    ],
    "excerpt": "https://github.com/sandipsahajoy/Predicting-Lymphoma-using-CNN-in-Keras/blob/master/README.md",
    "technique": "GitHub API"
  },
  "stargazers_count": {
    "confidence": [
      1.0
    ],
    "excerpt": {
      "count": 1,
      "date": "Tue, 21 Dec 2021 16:13:51 GMT"
    },
    "technique": "GitHub API"
  }
}